Show simple item record

dc.creatorErdemli, Gul
dc.creatorPriest, Birgit T.
dc.date.accessioned2020-10-06T20:27:02Z
dc.date.available2020-10-06T20:27:02Z
dc.date.created2015
dc.identifier.isbn978-2-88919-469-8
dc.identifier.issn1664-8714
dc.identifier.otherhttps://www.frontiersin.org/research-topics/1725/phenotypic-screening-in-the-21st-century
dc.identifier.urihttp://hdl.handle.net/20.500.12010/14277
dc.format.extent68 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherFrontiers Media SAspa
dc.subjectTherapeuticsspa
dc.subjectScience (General)spa
dc.subjectLabel-free technologiesspa
dc.titlePhenotypic screening in the 21st centuryspa
dc.subject.lembPhenotypic screenningspa
dc.subject.lembTarget-based assaysspa
dc.subject.lembSystems Biologyspa
dc.subject.lembPathwaysspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.localAbierto (Texto Completo)spa
dc.subject.keywordDrug Discoveryspa
dc.subject.keywordPanomic dataspa
dc.subject.keywordGene networks ---spa
dc.identifier.doi10.3389/978-2-88919-469-8
dc.relation.referencesPriest BT and Erdemli G (2014) Phenotypic screening in the 21st century. doi: 10.3389/fphar.2014.00264
dc.description.abstractenglishIn the genomic era of 1990s-2000s, pharmaceutical research moved to target-based drug discovery which enabled development of a number of small molecule drugs against a wide range of diseases. In many cases however, drugs that arose from genomics failed, questioning the validity of the targets and the suitability of target-based drug discovery as an optimal strategy for all disease states. For monogenic diseases, target-based approaches may be well-suited to the identification of novel therapies. Most diseases, however, are caused by a combination of several genetic and environmental factors and are likely to require simultaneous modulation of multiple molecular targets/pathways for successful treatment. For such diseases, reductionist approaches focusing on individual targets rather than biological networks are unlikely to succeed and new drug development strategies are required. In search of more successful approaches, the pharmaceutical industry is moving towards phenotypic screening beyond individual genes/targets. However, this requires rethinking of diseases and drug discovery approaches from a network and systems biology perspective. Since returning to the pre-genomics era of screening drug candidates in laborious animal models is not a feasible solution, the industry needs to evolve a new paradigm of phenotypic drug discovery within the context of systems biology. Such a paradigm must combine physiologically and disease relevant biological substrates with sufficient throughput, operational simplicity and statistical vigour. Biomarker strategies for translational medicine, as well as preclinical safety and selectivity assessments, would also need to be revised to adapt to the target agnostic style. This focused issue aims to discuss strategies, key concepts and technologies related to systems-based approaches in drug development. Design and implementation of innovative biological assays, featuring multiple target strategies, and rational drug design in the absence of target knowledge during the early drug discovery are illustrated with examples. Specific topics include: • The need for systems-based approaches in drug development • Phenotypic screening strategies • Compound libraries (natural product inspired compound collections) • Target deconvolution and identification • Target agnostic lead discovery and optimization • Multi-target approaches and decoding the phenotype (understanding biological interactions and multiscale systems modelling) • Translational aspects • Early evaluation of selectivity and safety in a target agnostic manner.spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2f33spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record